Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience.

@article{Klein2001IncreasedFH,
  title={Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience.},
  author={Karen Oerter Klein and Kevin M. Barnes and John Vann Jones and Penelope P Feuillan and Gordon B. Cutler},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2001},
  volume={86 10},
  pages={4711-6}
}
We report 98 children who have reached final adult height in a long-term trial of LHRH agonist treatment. These children were 5.3 +/- 2.1 yr old at the start of treatment and were treated with either deslorelin (4 microg/kg.d sc) or histrelin (4-10 microg/kg.d) for an average of 6.1 +/- 2.5 yr. Final height averaged 159.8 +/- 7.6 cm in the 80 girls, which was significantly greater than pretreatment predicted height (149.3 +/- 9.6 cm) but still significantly less than midparental height (MPH… CONTINUE READING